GlobeNewsWire
15 Jun 2026, 10:33 UTC · 13w ago
Verdict
Headline leans bearish. We score ADMA −1.00 across three claims.
Score confirms the headline.
Leans bearish
From its wording — no explicit rating
−1.00strongly bearish
What the story claims
3 claims · scored −1 bearish … +1 bullish
Culper Research alleges ADMA Biologics engaged in a channel stuffing scheme to report 20% growth in 2025 when real growth was actually -3%.
So whatAllegations of systemic revenue fraud and artificial growth are fundamental red flags that severely damage investor trust and valuation.
More negative than 99% of claims this week
A securities fraud class action lawsuit has been filed against ADMA Biologics and its senior executives following a nearly 30% stock price drop.
Continue reading
5 related stories
More negative than 96% of ticker scores this week
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
More negative than 91% of claims this week
Cantor downgraded ADMA Biologics' stock rating due to concerns raised by the short seller report.
More negative than 80% of claims this week
Which stocks this story touches
More negative than 96% of ticker scores this week
The company is facing a securities fraud class action lawsuit following allegations of channel stuffing and a significant stock price drop.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Newsfile Corp
2h ago
+7.8%
Price is moving against the score
$8.85 vs $8.21 close before publication (Jun 12) · not market-adjusted
ADMA chart →
